Download PDF
CC BY 4.0 · Journal of Child Science 2022; 12(01): e112-e116
DOI: 10.1055/s-0042-1757144
Original Article

Outcome of Pediatric Anti-N-Methyl-D-Aspartate (NMDA) Receptor Encephalitis in Rural Area of Thailand

Vitchayaporn Emarach Saengow
1   Department of Pediatrics, Maharat Nakhon Ratchasima Hospital, Nakhon Ratchasima, Thailand
,
Kasama Bhudhisawasdi
2   Department of Pediatrics. Khon Kaen Hospital, Khon Kaen, Thailand
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis has a very good outcome; however, there are few reports in developing countries regarding the outcome of pediatric anti-NMDAR encephalitis. We aimed to report the clinical outcome of pediatric anti-NMDAR encephalitis in the rural area of Thailand. This retrospective cohort study recruited children between the age of 1 month and 15 years with the diagnosis of anti-NMDAR encephalitis admitted at Maharat Nakhon Ratchasima Hospital from 1st May 2015 to 31th March 2020. Baseline characteristics and investigation were recorded. The first-line treatment was intravenous pulse methylprednisolone alone, pulse methylprednisolone plus intravenous immune globulin (IVIG), or IVIG alone. The second-line treatment was monthly intravenous cyclophosphamide or azathioprine. The modified Rankin Scale (MRS) was used for evaluation at 1, 3, 6, 12, 18, and 24 months after receiving first-line treatment to determine clinical outcomes. The factors that may affect the outcomes were evaluated. In total, 17 patients were recruited, with the mean age of 8 years, and 76.46% were female. 82.35% of patients developed seizures, and 52.94% turned to status epilepticus. 70.59% received first-line treatment as pulse methylprednisolone plus IVIG. 82.35% received complete follow-up at 12 months. According to MRS score, at first diagnosis 94.12% reported severe disability, at 1 month after receiving treatment, 47.06% improved to moderate–mild disability, and at 6 and 12 months, 40% and 78.57% had complete recovery, respectively. Different types of first-line and second-line treatments did not affect the clinical outcome. Comorbidity of status epilepticus affected MRS. Anti-NMDAR encephalitis has a very good prognosis; prompt diagnosis is necessary. Comorbidity as status epilepticus may affect the clinical outcome.

Keywords

Anti-NMDAR encephalitis - Pediatric - Outcome - Factors


Publication History

Received: 13 April 2022

Accepted: 28 June 2022

Article published online:
29 September 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Graus F, Titulaer MJ, Balu R. et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 2016; 15 (04) 391-404
    CrossrefPubMedGoogle Scholar
  • 2 Dalmau J, Tüzün E, Wu HY. et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007; 61 (01) 25-36
    CrossrefPubMedGoogle Scholar
  • 3 Dalmau J, Gleichman AJ, Hughes EG. et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008; 7 (12) 1091-1098
    CrossrefPubMedGoogle Scholar
  • 4 Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011; 10 (01) 63-74
    CrossrefPubMedGoogle Scholar
  • 5 Titulaer MF, McCracken L, Gabilonda I. et al. Treatment and prognostic factors for long-term outcome in patients with anti-N-methyl-D-aspartate (NMDA) receptor encephalitis: a cohort study. Lancet Neurol 2013; 12 (02) 157-165
    CrossrefPubMedGoogle Scholar
  • 6 Florance NR, Davis RL, Lam C. et al. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol 2009; 66 (01) 11-18
    CrossrefPubMedGoogle Scholar
  • 7 Pruetarat N, Netbaramee W, Pattharathitikul S, Veeravigrom M. Clinical manifestations, treatment outcomes, and prognostic factors of pediatric anti-NMDAR encephalitis in tertiary care hospitals: a multicenter retrospective/prospective cohort study. Brain Dev 2019; 41 (05) 436-442
    CrossrefPubMedGoogle Scholar
  • 8 Broadley J, Seneviratne U, Beech P. et al. Prognosticating autoimmune encephalitis: a systematic review. J Autoimmun 2019; 96: 24-34
    CrossrefPubMedGoogle Scholar
  • 9 Kong SS, Chen YJ, Su IC. et al; CHEESE Study Group. Immunotherapy for anti-NMDA receptor encephalitis: experience from a single center in Taiwan. Pediatr Neonatol 2019; 60 (04) 417-422
    CrossrefPubMedGoogle Scholar
  • 10 Zhang L, Wu MQ, Hao ZL. et al. Clinical characteristics, treatments, and outcomes of patients with anti-N-methyl-d-aspartate receptor encephalitis: a systematic review of reported cases. Epilepsy Behav 2017; 68: 57-65
    CrossrefPubMedGoogle Scholar
  • 11 Saraya AW, Worachotsueptrakun K, Vutipongsatorn K, Sonpee C, Hemachudha T. Differences and diversity of autoimmune encephalitis in 77 cases from a single tertiary care center. BMC Neurol 2019; 19 (01) 273
    CrossrefPubMedGoogle Scholar
  • 12 Xu X, Lu Q, Huang Y. et al. Anti-NMDAR encephalitis: a single-center, longitudinal study in China. Neurol Neuroimmunol Neuroinflamm 2019; 7 (01) 633
    CrossrefPubMedGoogle Scholar